

Duvelisib, PI3K delta/gamma inhibitor

Catalog	Unit
TBI4788-5MG	5 mg
TBI4788-25MG	25 mg

Product Details

Formal Name: 8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one

Alternate Names: IPI-145

Molecular Formula: C₂₂H₁₇ClN₆O

Formula Weight: 416.87

CAS Number: 1201438-56-3


Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to at least 25 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.



Applications

PI3K delta/gamma inhibitor

Functions

Duvelisib (1201438-56-3) is a potent and selective (IC₅₀'s: PI3K α = 1602nM, PI3K β = 85nM, PI3K δ = 2.5nM, PI3K γ = 27nM) dual PI3K δ/γ inhibitor. It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells. Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others. Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells. Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes

Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.